Business Context and Reporting Period
This Form 8-K Current Report for Bruker Corporation was filed on February 12, 2013, with a report date of February 19, 2013. The filing primarily serves to announce the election of a new director and to reference a press release containing financial results for the quarter and full year ended December 31, 2012.
Key Financial Metrics
The filing text references a press release (Exhibit 99.1) containing combined financial results for the three and twelve months ended December 31, 2012. However, the specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity are not included in the body of this 8-K document. The filing states that the information in the attached press release is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Material Changes
No material changes to financial operations or conditions are detailed within the text of this filing. The document directs readers to the attached press release for operational results but does not summarize year-over-year comparisons or specific variances in the main text.
Corporate Governance and Management Commentary
- Election of New Director: On February 12, 2013, the Board of Directors elected Marc A. Kastner, Ph.D., to fill a vacancy on the Board, effective immediately.
- Director Profile: Dr. Kastner is the Donner Professor of Science and Dean of the MIT School of Science at the Massachusetts Institute of Technology (MIT). He has held the Dean position since 2007 and the Professorship since 1989.
- Term and Compensation: Dr. Kastner will serve as a Class II director until the 2014 Annual Meeting of Stockholders. His compensation will be consistent with other non-employee directors as described in the 2012 proxy statement.
- Conflicts of Interest: The filing states there are no other arrangements or understandings regarding his election, and he is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 19, 2013) for specific Q4 and Full Year 2012 financial figures, as they are not present in the 8-K text.
- Verify the details of Dr. Kastner's compensation package in the Company's definitive proxy statement filed on April 13, 2012.
- Confirm the status of the second Board vacancy mentioned in the filing, as Dr. Kastner was elected to fill "one of two vacancies."